U.S. Food and Drug Administration Approves Camzyos™
Bristol Myers Squibb, a member of Bio Nebraska, announced last week that the FDA approved Camzyos™ for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms.
2022 NIAMRRE Annual Conference
Join NIAMRRE in Lincoln, Nebraska for their 2022 Annual Conference, May 16-18, 2022.
Member Spotlight: MatMaCorp
For our May Member Spotlight we talked to MatMaCorp, a Lincoln-based molecular diagnostics company that develops, manufacturers, and sells portable devices and testing solutions for the research, agriculture, veterinary health, and human diagnostics markets.
Merck Animal Health Introduces New Tools to Assist Caretakers in Managing Herd Health
Merck Animal Health, a member of Bio Nebraska, recently introduced the Herd Health Manager and Feedlot Diseases App to help caretakers manage important cattle health information.
Thyreos awarded Small Business Innovation Research grant
Thyreos, a member of Bio Nebraska, has been awarded an SBIR grant to develop a new vaccine to protect against Infectious Bovine Rhinotracheitis (IBR), a disease that causes respiratory illness in cattle.
Welcome Whiting-Turner
We are excited to welcome new Bio Nebraska member, Whiting-Turner.
Kirk Zeller wins Excellence in Entrepreneurship award
Kirk Zeller, founder of the Silicon Prairie Center and co-founder of Progressive NEURO, won the Excellence in Entrepreneurship award at the University of Nebraska at Kearney’s Light it Up! celebration on April 14.
Farritor wins inaugural NU faculty commercialization honor
Shane Farritor, co-founder and chief technology officer of Virtual Incision, is the inaugural winner of the University of Nebraska system’s Faculty IP Innovation and Commercialization Award. Virtual Incision, a member of Bio Nebraska, is working to commercialize miniature surgical robots for minimally invasive procedures.
Welcome Prolytix
We are excited to welcome new Bio Nebraska member, Prolytix.
Novartis Pluvicto™ approved by FDA
Novartis, a member of Bio Nebraska, announced that the FDA approved Pluvicto, a targeted radioligand therapy (RLT) for eligible patients with metastatic castration-resistant prostate cancer. Pluvicto is expected to be available to physicians and patients within weeks.